Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprenetapopt + Pembrolizumab in Solid Tumors
NCT04383938Phase 2Completed
- Sponsor
- Aprea Therapeutics
- Start
- Jun 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eprenetapopt in solid tumor, gastric cancer (GC), bladder cancer and 2 more (4 arms), sponsored by Aprea Therapeutics. Primary endpoints: Safety and Tolerability at 1 year and Recommended Phase 2 Dose at 21 days. Started Jun 2020; status: completed.
02
Drugs
eprenetapopt
03
Conditions
solid tumorgastric cancer (GC)bladder cancernon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04383938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383938.